Jane Street Group, LLC Inhibrx, Inc. Transaction History

Jane Street Group, LLC

  • $445 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$32.76 - $39.56 $381,064 - $460,161
-11,632 Reduced 30.65%
26,314 $919,000
Q4 2023

Feb 14, 2024
SELL
$14.5 - $38.0 $63,350 - $166,022
-4,369 Reduced 10.32%
37,946 $1.44 Million
Q3 2023

Nov 14, 2023
SELL
$15.75 - $26.31 $27,342 - $45,674
-1,736 Reduced 3.94%
42,315 $776,000
Q2 2023

Aug 14, 2023
SELL
$16.96 - $27.82 $675,584 - $1.11 Million
-39,834 Reduced 47.49%
44,051 $1.14 Million
Q1 2023

May 15, 2023
BUY
$18.45 - $27.14 $1.55 Million - $2.28 Million
83,885 New
83,885 $1.58 Million

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email